KRRO Financials: Revenue Breakdown, Margins & Competitor Comparison
This article provides an overview of Korro Bio Inc's (KRRO) financial performance, focusing on its profitability margins and comparing them to competitors DERM and MENS. KRRO exhibits a high gross margin but significant negative operating and net margins, alongside a negative Return on Equity, indicating challenges in converting operations into shareholder value. The company, with a market capitalization of $201.92M, shows a strong gross margin compared to DERM.
Lynx1 fund tied to Weston Nichols adds Korro Bio (KRRO) position
Lynx1 Master Fund LP, associated with Lynx1 Capital Management LP and Weston Nichols, has purchased 520 shares of Korro Bio, Inc. (KRRO) common stock at $10.60 per share, as reported in a recent SEC Form 4 filing. This transaction brings their indirect holdings to 1,538,296 shares. Both Lynx1 Capital Management LP and Weston Nichols disclaim beneficial ownership except for any pecuniary interest.
Lynx1 and Weston Nichols report 1.54M shares in Korro Bio (NASDAQ: KRRO)
Lynx1 Capital Management LP and Weston Nichols have filed an amended passive investment disclosure (Schedule 13G/A) for Korro Bio, Inc. (NASDAQ: KRRO). They reported beneficial ownership of 1,538,296 shares of Common Stock, which represents a 10.7% stake in the company. This ownership includes shared voting and shared dispositive power over the shares, based on 14,422,571 shares outstanding as of March 11, 2026.
Lynx1 Capital buys Korro Bio (KRRO) shares worth $5512
Lynx1 Capital Management L.P., a ten percent owner of Korro Bio, Inc. (NASDAQ:KRRO), recently purchased 520 shares for $5,512, at a price of $10.60 per share. This transaction led to a 30% gain as the stock climbed to $13.85, contributing to KRRO's significant weekly and year-to-date returns. The company has also secured $85 million in private equity financing and received multiple analyst upgrades, reflecting optimism from both investors and analysts.
KRRO Price Today: Korro Bio, Inc. Stock Price, Quote & Chart
Korro Bio, Inc. (KRRO) is currently trading at $11.32, remaining unchanged from its previous close. The stock has seen a +5.26% return over the past month but experienced a -29.06% price change over the last 12 months, indicating weak performance. Korro Bio, Inc. is a biopharmaceutical company focused on developing genetic medicines through RNA editing for various diseases.
JPMorgan Chase & Co. Buys 196,079 Shares of Korro Bio, Inc. $KRRO
JPMorgan Chase & Co. significantly increased its stake in Korro Bio, Inc. by 6,185.5% in the third quarter, acquiring an additional 196,079 shares to a total of 199,249 shares valued at $9.54 million. This move coincides with substantial insider buying, as two major shareholders each bought 207,100 shares in March, contributing to a total of 1.66 million insider purchases worth $18.4 million over the last 90 days. Despite this investor confidence, Korro Bio reported an unprofitable Q4 with an EPS of ($5.32).
Korro Bio, Inc. (NASDAQ:KRRO) Given Average Recommendation of "Moderate Buy" by Brokerages
Eleven research firms have given Korro Bio, Inc. (NASDAQ:KRRO) a consensus "Moderate Buy" rating, with an average 12-month target price of $37.29. This comes despite the company missing its Q4 EPS estimates significantly, reporting ($5.32) versus ($1.93) estimated, and having negative net margins. Insiders, notably Edward T. Mathers and Paul Edward Walker, recently purchased substantial shares, increasing their ownership to 4.60%.
Vanguard (KRRO) reports zero beneficial ownership after realignment
The Vanguard Group has filed an amendment to a Schedule 13G/A, reporting 0% beneficial ownership of Korro Bio (KRRO) common stock. This change is due to an internal realignment on January 12, 2026, where certain Vanguard subsidiaries will now report their holdings separately, as permitted by SEC Release No. 34-39538. Vanguard itself no longer claims beneficial ownership over securities held by these realigned subsidiaries.
Korro Bio stock gains after tough 2025 - new drug candidate, analyst upgrades boost outlook
Korro Bio's stock experienced gains following a challenging 2025, driven by the announcement of a new drug candidate and positive analyst upgrades. These developments suggest an improved outlook for the company after a difficult previous year.
[EFFECT] Korro Bio, Inc. SEC Filing
This article reports on an SEC filing (Form EFFECT) by Korro Bio, Inc. (KRRO) which was declared effective on March 20, 2026, at 4:15 P.M. The filing indicates a Neutral impact and sentiment for the company. It also provides an overview of Korro Bio's stock data, recent news, and other SEC filings.
Korro Bio (NASDAQ: KRRO) registers 7.65M shares for resale after $85M private placement
Korro Bio (NASDAQ: KRRO) has registered 7,650,764 shares of common stock for resale following an $85 million private placement that closed on March 10, 2026. This registration includes 4,501,928 common shares and 3,148,836 shares issuable upon the exercise of pre-funded warrants. The company will not receive proceeds from the sale of these shares by the selling stockholders, except for a nominal exercise price from pre-funded warrants.
Korro Bio, Inc. (KRRO) reports Q4 loss, lags revenue estimates
Korro Bio, Inc. (KRRO) announced its Q4 earnings, reporting a loss that was narrower than anticipated by Wall Street analysts but failing to meet revenue expectations. The biotechnology company reported an adjusted loss per share of -$0.98 against an estimated -$1.00, while its revenue of $1 million fell short of the projected $6.83 million.
Analysts Offer Insights on Healthcare Companies: Korro Bio (KRRO), Oruka Therapeutics (ORKA) and Gilead Sciences (GILD)
Analysts have provided insights on several healthcare companies, including Korro Bio (KRRO), Oruka Therapeutics (ORKA), and Gilead Sciences (GILD). Korro Bio and Oruka Therapeutics received "Strong Buy" consensus ratings with significant upside potential, while Gilead Sciences received a "Strong Buy" consensus but a "Hold" rating from one analyst. Price targets and analyst performance metrics were also detailed for each company.
Korro Bio Stock Gains After Tough 2025 - New Drug Candidate, Analyst Upgrades Boost Outlook
Korro Bio's shares gained after a challenging 2025, driven by financial results, a new lead drug candidate KRRO-121 for hyperammonemia, and analyst upgrades. Despite a net loss in 2025, the company has a cash position expected to last until late 2028 and increased collaboration revenue with Novo Nordisk. Analysts from Raymond James and Cantor Fitzgerald upgraded their ratings and price forecasts, signaling a more positive outlook for the company's future.
Analysts Offer Insights on Healthcare Companies: Korro Bio (KRRO), Sagimet Biosciences, Inc. Class A (SGMT) and Bristol-Myers Squibb (BMY)
This article provides analyst insights on three healthcare companies: Korro Bio (KRRO), Sagimet Biosciences, Inc. Class A (SGMT), and Bristol-Myers Squibb (BMY). Ryan Deschner of Raymond James upgraded Korro Bio to Buy, while Jay Olson of Oppenheimer maintained a Buy rating on Sagimet Biosciences. Bernstein's Courtney Breen maintained a Hold rating on Bristol-Myers Squibb.
Korro Bio (KRRO) Losses Of US$117.3 Million Test Bullish Narratives On Profitability
Korro Bio (KRRO) reported a net loss of US$117.3 million and a basic EPS loss of US$12.48 for FY 2025, with Q4 revenue of US$1.3 million. The company's revenue base remains small at US$6.4 million, and losses have widened despite revenue growth in earlier quarters. Bearish arguments suggest continued pressure on the bottom line, with forecasts indicating revenue decline and a high P/S multiple compared to peers, raising concerns about future dilution risks.
Korro Bio (KRRO) sellers register 7.65M common shares after $85M private placement
Korro Bio (KRRO) has filed a shelf registration to allow selling stockholders to resell up to 7.65 million common shares, which includes common shares and pre-funded warrants issued during a March 9, 2026 private placement that raised $85 million. The company clarified that it will not receive proceeds from these secondary resales, except for a nominal exercise price from cash exercises of pre-funded warrants. The registration outlines the distribution plan for these shares, specifying that selling stockholders can use various methods from open market transactions to privately negotiated sales.
Korro Bio (KRRO) major holder adds stock and pre-funded warrants in March 2026 buy
Edward T. Mathers, an affiliated manager of major holder New Enterprise Associates 17, L.P., acquired additional Korro Bio (KRRO) securities on March 10, 2026. This transaction included 242,945 Pre-Funded Warrants and 207,100 shares of Common Stock, documented in an SEC Form 4 filing. Following these purchases, indirect holdings of Common Stock totaled 1,297,893 shares.
Major Korro Bio (KRRO) holder adds shares and pre-funded warrants in March 10 Form 4
New Enterprise Associates 17, L.P. (NEA 17), a significant indirect holder of Korro Bio (KRRO), acquired 242,945 Pre-Funded Warrants and 207,100 shares of Common Stock on March 10, 2026. These transactions, detailed in a Form 4 filing, involved prices of approximately $11.11 per warrant and share, respectively. Following these purchases, NEA 17 indirectly holds 1,297,893 shares of Common Stock, with the warrants being exercisable subject to a 9.99% ownership cap.
Korro Bio (KRRO) Losses Of US$117.3 Million Test Bullish Narratives On Profitability
Korro Bio (KRRO) reported a net loss of US$117.3 million and a basic EPS loss of US$12.48 for the trailing 12 months, with quarterly net losses in FY 2025 ranging from US$18.1 million to US$50.0 million. The company's small revenue base of US$6.4 million, coupled with forecasts of a 45.8% annual decline in revenue for the next three years, challenges bullish narratives. Furthermore, Korro Bio's high Price-to-Sales (P/S) ratio of 28.9x, significantly higher than peers, and substantial shareholder dilution, raise concerns for investors given its unprofitability.
Cantor Fitzgerald raises Korro Bio stock price target on UCD confidence
Cantor Fitzgerald reaffirmed an Overweight rating on Korro Bio Inc. (NASDAQ:KRRO) and increased its price target to $22.00, citing enhanced confidence in the company’s urea cycle disorder (UCD) clinical development program. Korro Bio plans to file an IND/CTA for KRRO-121 in hyperammonemia in patients with UCD and hepatic encephalopathy in the second half of 2026, with Phase 1 study design details to follow the filing. This positive outlook is further supported by recent successful private equity financing and upgrades from other analysts like Raymond James, Clear Street, and H.C. Wainwright, reflecting growing confidence in Korro Bio's RNA editing therapeutics.
Raymond James upgrades Korro Bio stock rating on hyperammonemia pivot
Raymond James upgraded Korro Bio Inc. (NASDAQ:KRRO) from Market Perform to Outperform, setting a price target of $23.00, due to the company's strategic pivot into hyperammonemia indications. This upgrade follows positive preclinical data and an $85 million PIPE financing, extending Korro Bio's cash runway and offering a clear path to potential proof-of-concept for its promising new programs. The company also received similar upgrades from Clear Street, H.C. Wainwright, and Piper Sandler, reflecting growing confidence in its innovative approach to treating complex liver conditions.
Korro Bio (KRRO) secures $85M PIPE to extend cash runway into 2028
Korro Bio has secured an $85 million private investment in public equity (PIPE) financing, significantly extending its cash runway into the second half of 2028. This capital infusion, combined with existing cash, will fund the advancement of its RNA editing pipeline, including clinical data for KRRO-121 in urea cycle disorders, a GalNAc-conjugated alpha-1 antitrypsin deficiency program, and a longevity and liver health program. The financing involved selling common stock and pre-funded warrants to institutional investors, led by Venrock Healthcare Capital Partners.
NEA 17 fund boosts Korro Bio (KRRO) stake with stock and pre-funded warrants
New Enterprise Associates 17, L.P. (NEA 17), a 10% owner of Korro Bio, Inc. (KRRO), increased its stake by acquiring 207,100 shares of common stock and 242,945 pre-funded warrants. These acquisitions, made through a Subscription Agreement, demonstrate a significant investment in Korro Bio, with the warrants having specific exercise conditions related to ownership caps. Following these transactions, NEA 17 beneficially owns 1,297,893 shares of common stock and 242,945 pre-funded warrants.
Korro Bio (KRRO) holder adds shares, pre-funded warrants in March buy
A Form 4 SEC filing reveals that entities linked to Scott D. Sandell, a 10% owner of Korro Bio, Inc. (KRRO), indirectly acquired 242,945 Pre-Funded Warrants and 207,100 shares of Common Stock on March 10, 2026. These transactions were made pursuant to a Subscription Agreement, with the pre-funded warrants having a $0.001 exercise price and subject to ownership caps. The filing indicates a positive sentiment regarding this insider trading activity.
Insider fund tied to Carmen Chang boosts Korro Bio (KRRO) stake with 450,045 buys
An entity associated with 10% owner Carmen Chang indirectly acquired 450,045 securities of Korro Bio (KRRO), consisting of 242,945 Pre-Funded Warrants and 207,100 shares of Common Stock. These acquisitions, made on March 10, 2026, were part of a Subscription Agreement with the company rather than open-market trading. The Pre-Funded Warrants have specific exercise rules, including a beneficial ownership cap, and Chang disclaims personal pecuniary interest in the holdings.
Korro Bio (NASDAQ: KRRO) expands RNA-editing pipeline as 2025 net loss deepens
Korro Bio reported a widening net loss in 2025 to $117.3 million, up from $83.6 million in 2024, despite an increase in collaboration revenue and progress in its RNA-editing pipeline. The company nominated KRRO-121 as a development candidate for hyperammonemia and advanced its alpha-1 antitrypsin deficiency program. An $85 million private placement in March 2026 is expected to extend Korro Bio's cash runway into the second half of 2028.
Nea 17 buys Korro Bio (KRRO) shares worth $2.3 million
Edward T. Mathers, a ten percent owner of Korro Bio, Inc. (KRRO), recently purchased 207,100 shares of common stock for $2.3 million at $11.11 per share, and also acquired 242,945 Pre-Funded Warrants. This transaction occurred on March 10, 2026, ahead of the company's earnings report on March 18. The purchase follows an $85 million private investment and multiple analyst upgrades due to the potential of their lead program, KRRO-121.
Korro Bio, Inc. (KRRO) Announces Fourth Quarter Loss, Falls Short of Revenue Expectations
Korro Bio, Inc. (KRRO) reported a larger-than-expected quarterly loss of $5.32 per share, significantly missing analyst estimates and falling short of revenue expectations with $1.29 million. Despite outperforming the broader market year-to-date, the company's financial outlook remains negative, earning it a Zacks Rank #4 (Sell). Investors are advised to monitor future earnings forecasts and estimate revisions keenly.
Korro Bio raises $85 million in private equity financing
Korro Bio Inc. has successfully secured $85 million in private equity financing, led by Venrock Healthcare Capital Partners, through a private investment in public equity (PIPE) agreement. This funding, which includes the sale of common stock and pre-funded warrants, is expected to extend the company's cash runway into the second half of 2028. The proceeds will support clinical development for pipeline assets, including KRRO-121 for hyperammonemia, a GalNAc-conjugated oligonucleotide program, and a longevity and liver health program, garnering positive analyst upgrades.
Korro Bio extends cash runway after trial fail, layoffs
Korro Bio, a Cambridge-based company, has secured new financing to extend its cash runway until 2028. This move comes after the company cut 34% of its workforce in November following the failure of its only clinical-stage drug. The new funds will allow Korro Bio to pursue clinical data for its preclinical assets.
Korro Announces $85 Million Private Placement
Korro Bio, Inc. announced an $85 million private investment in public equity (PIPE) financing. This funding, combined with existing cash, will extend Korro's cash runway into the second half of 2028, supporting its RNA editing pipeline for genetic diseases. The PIPE financing was led by Venrock Healthcare Capital Partners, with participation from several new and existing investors.
Korro Bio Raises $85 Million in Private Placement, Adds Investor Registration Rights
Korro Bio has successfully raised $85.0 million through a private placement of common stock and pre-funded warrants, led by Venrock Healthcare Capital Partners. This financing, which includes a registration rights agreement, is expected to fund the company's operations into the second half of 2028 and advance its OPERA RNA editing pipeline. The agreements aim to provide investor liquidity and support the company's capital needs.
Investors pour $85M into RNA editor Korro Bio’s genetic disease drugs
Korro Bio announced an oversubscribed private placement expected to raise approximately $85 million, led by Venrock Healthcare Capital Partners. This financing, combined with existing cash, is projected to extend Korro's cash runway into the second half of 2028. The funds will support the clinical development and data milestones for KRRO-121, an AATD GalNAc program, and other pipeline initiatives focused on RNA editing for genetic diseases.
Korro Bio Announces Oversubscribed $85M PIPE Financing
Korro Bio (KRRO) has successfully secured an oversubscribed $85 million PIPE financing, led by Venrock Healthcare Capital Partners, which closed on March 10, 2026. This significant capital raise extends Korro's cash runway into late 2028 and will fund critical clinical milestones for its RNA editing programs, including KRRO-121 for hyperammonemia and a GalNAc-conjugated candidate for alpha-1 antitrypsin deficiency, as well as a liver health program. Despite strong investor confidence in its technology, TipRanks' AI Analyst Spark rates KRRO as Neutral due to ongoing losses and heavy cash burn.
KRRO Stock News Today | Earnings, Events & Price Alerts
This page provides news and event updates for KRRO stock, including analyst rating adjustments and reports on trial results. Recent news highlights include analyst upgrades for Korro Bio's KRRO-121 and subsequent downgrades following disappointing trial results, as well as broader market movements. The platform also offers sections for earnings analysis and a monitor for news related to KRRO.
Korro Bio, Inc. CEO Ram Aiyar to Present at TD Cowen 46th Annual Health Care Conference
Korro Bio, Inc.'s CEO, Dr. Ram Aiyar, is scheduled to present at the TD Cowen 46th Annual Health Care Conference. The company, focused on RNA editing for genetic medicines, aims to showcase its innovative approach to treating rare and prevalent diseases. This presentation offers Korro Bio an opportunity to enhance its visibility, attract investors, and potentially secure partnerships within the biopharmaceutical industry.
KRRO - Korro Bio, Inc. Latest Stock News & Market Updates
This page provides the latest news and insights on Korro Bio, Inc. (KRRO), a clinical-stage biopharmaceutical company focused on RNA editing for genetic medicines. Key updates include the progress of its lead candidate KRRO-110 for Alpha-1 Antitrypsin Deficiency, pipeline advancements for KRRO-121, financial results, and corporate developments. The article also lists recent news releases from Korro Bio, detailing events such as private placements, investor conferences, and financial reporting.
KRRO Financials: Income Statement, Balance Sheet & Cash Flow
This article provides a detailed financial overview of Korro Bio, Inc. (KRRO), including its income statement, balance sheet, and cash flow statement. It highlights the company's financial health score as 49/100, driven by low profitability (operating margin of -4047.1%), strong liquidity with a current ratio of 8.79, and a weak Piotroski F-Score of 2/9. Key metrics for fiscal year 2024 include $2.3M in revenue, -$83.6M net income, and an estimated cash runway of 11 months, indicating challenges in profitability and cash generation despite a strong balance sheet.
Korro Bio (KRRO) Price Target Increased by 12.61% to 19.53
Fintel reports that the average one-year price target for Korro Bio (NasdaqCM:KRRO) has been raised by 12.61% to $19.53 per share, up from $17.34. This new target represents a 63.67% increase from the last closing price of $11.93. Institutional ownership data shows 142 funds holding positions in the company, with Atlas Venture Life Science Advisors and NEA Management Company being among the largest holders.
Korro to Present at the TD Cowen 46th Annual Health Care Conference
Korro Bio, Inc. announced that its CEO and President, Ram Aiyar, Ph.D., will present at the upcoming TD Cowen 46th Annual Health Care Conference. The presentation, scheduled for March 3, 2026, will highlight Korro's work as a biopharmaceutical company developing genetic medicines based on editing RNA for various diseases. Korro focuses on harnessing the body's natural RNA editing process to create precise and tunable genetic treatments.
Korro Bio, Inc. CEO Ram Aiyar to Present at TD Cowen 46th Annual Health Care Conference
Korro Bio, Inc. announced that its CEO, Dr. Ram Aiyar, will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026, at 11:10 a.m. ET. The biopharmaceutical company focuses on developing genetic medicines through RNA editing for rare and common diseases. This presentation aims to highlight Korro Bio's innovative approach and proprietary technology to investors and industry professionals.
RNA medicine developer Korro to present at three-day Boston health conference
Korro Bio announced that CEO Ram Aiyar, Ph.D., will present at the TD Cowen 46th Annual Health Care Conference in Boston on March 3, 2026. The presentation will detail the company's work on RNA editing for genetic medicines. The company's stock, KRRO, has seen mixed performance around past investor-facing events, with significant moves often tied to conference appearances, analyst days, and earnings reports, which investors closely watch for updates on its pipeline and financial status.
Korro to Present at the TD Cowen 46th Annual Health Care Conference
Korro Bio, Inc. (Nasdaq: KRRO) announced that its CEO and President, Ram Aiyar, Ph.D., will present at the TD Cowen 46th Annual Health Care Conference. The presentation is scheduled for Tuesday, March 3, 2026, at 11:10 a.m. ET in Boston, MA. Korro Bio is a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for various diseases.
Point72 entities report 2.9% Korro Bio (KRRO) stake in amended 13G
Point72-affiliated entities, including Point72 Biotech Private Investments, Differentiated Ventures Investments, 72 Investment Holdings, and Steven A. Cohen, have reported an amended 2.9% passive stake in Korro Bio, Inc. (KRRO) common stock. As of December 31, 2025, these entities beneficially own 276,831 shares. The filing clarifies that Point72 Asset Management and Point72 Capital Advisors do not hold shares directly but manage and control affiliated entities, and the stake is not intended to influence company control.
Clear Street upgrades Korro Bio stock rating on hyperammonemia program potential
Clear Street has upgraded Korro Bio Inc. (NASDAQ:KRRO) from Hold to Buy and raised its price target to $18 from $10, based on the potential of its new hyperammonemia program, KRRO-121. The firm believes this program addresses an unmet medical need with strong scientific backing, offering a favorable risk/reward profile at current trading levels. This upgrade follows similar positive revisions from other analysts, although some firms maintain a Market Perform rating, acknowledging remaining clinical de-risking and past program setbacks.
Driehaus exits Korro Bio (KRRO) stake in amended 13G/A filing
Driehaus Capital Management LLC has filed an amended 13G/A, reporting that it no longer holds any beneficial ownership in Korro Bio, Inc. (KRRO). The filing indicates that as of December 31, 2025, Driehaus owns 0 shares, representing 0% of the common stock, marking an exit from its previous stake in the company. This disclosure confirms Driehaus holds no voting or dispositive power over Korro Bio shares.
Clear Street upgrades Korro Bio stock rating on hyperammonemia program potential
Clear Street upgraded Korro Bio Inc. (NASDAQ:KRRO) to Buy from Hold, raising its price target to $18.00, following an analyst day that highlighted KRRO-121, a new lead program for hyperammonemia. The firm sees strong scientific rationale and significant value potential by 2027, despite remaining clinical risks. Other analysts, including H.C. Wainwright, Piper Sandler, and Chardan Capital Markets, also upgraded Korro Bio, focusing on the promise of KRRO-121, which is expected to enter clinical trials late in 2026.
William Blair Upgrades Korro Bio (KRRO)
William Blair has upgraded Korro Bio (KRRO) from Market Perform to Outperform. The average one-year price target for KRRO is $17.34, suggesting a 55.24% upside from its last closing price. Institutional ownership in Korro Bio shows increased shares, indicating a bullish outlook.
Korro Bio (NASDAQ:KRRO) Upgraded to "Outperform" at William Blair
William Blair has upgraded Korro Bio (NASDAQ:KRRO) from "market perform" to "outperform." Despite mixed analyst sentiment and a consensual "Hold" rating with an average $66.50 price target, the stock opened at $11.17 and has a market cap of approximately $105.2 million. Institutional investors hold about 13.18% of the shares.
